Do you have moderate to severe plaque psoriasis? We need your valuable input.
The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for duobrii for moderate to severe plaque psoriasis.
The CDR is part of the Canadian Agency for Drugs and Technologies in Health (CADTH). The CDR conducts objective, rigorous reviews of the clinical and cost effectiveness of drugs, and provides formulary listing recommendations to the publicly funded drug plans in Canada (except Quebec).
To help them make their recommendations, the CDR accepts input from patient organizations and groups, like Arthritis Consumer Experts (ACE). Because patient input is vitally important to government decision-making about medications, we would like to gather your views and share them with the CDR.
These are the questions they are asking:
- What are the plaque psoriasis related symptoms and problems that impact the patients’ day-to-day life and quality of life? For example: what aspects of plaque psoriasis are more important to control, how does plaque psoriasis affect day-to-day life, and are there any activities that the patient is not able to do as a result of plaque psoriasis?
- How well are patients managing their plaque psoriasis with currently available treatments? Examples of the types of information to be included in the answer are:
- What therapy are patients using for plaque psoriasis?
- How effective is current therapy in controlling the common aspects of plaque psoriasis?
- Are there adverse effects that are more difficult to tolerate than others?
- Are there hardships in accessing current therapy?
- Are there hardships in receiving the treatment (swallowing pills, infusion lines)?
- Are there needs, experienced by some or many patients, which are not being met by current therapy?
- What are these needs?
- What challenges do caregivers face in caring for patients with plaque psoriasis?
- How do treatments impact on the caregivers’ daily routine or lifestyle?
- Are there challenges in dealing with adverse effects related to current therapy?
- Based on no experience with duobrii for the treatment of plaque psoriasis, what are the expectations for the medication?
- Is it expected that the lives of patients will be improved by duobrii, and how?
- Is there a particular gap or unmet patient need in current therapy that duobrii will help alleviate?
- Would patients be willing to experience serious adverse effects with duobrii if they experienced other benefits from the medication?
- How much improvement in the condition would be considered adequate? What other benefits might duobrii have, for example, fewer hospital visits or less time off work?
- What experiences have patients had to date with duobrii as part of a clinical trial or through a manufacturer’s compassionate supply?
- What positive and negative effects does duobrii have on the condition?
- Which symptoms does duobrii manage better than the existing therapy and which ones does it manage less effectively?
- Does duobrii cause adverse effects?
- Which adverse effects are acceptable and which ones are not?
- Is duobrii easier to use?
- How is duobrii expected to change a patient’s long-term health and wellbeing?
If you live with plaque psoriasis or care for someone with plaque psoriasis, please send us your input by Tuesday, February 11, so that we may make a submission by the February 14th deadline. Your input will be anonymous.
Please complete the online questionnaire or contact us at feedback@jointhealth.org to provide your input or arrange for a phone interview at 604-974-1366.